Baird analyst Catherine Schulte lowered the firm’s price target on Bio-Techne to $90 from $100 and keeps an Outperform rating on the shares. The firm said they reported mixed 4Q results, with organic revenue growth below expectations largely due to China, but earnings per share were in line with Street.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TECH: